Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Cancer Res. 2012 Dec 15;72(24):6338-43. doi: 10.1158/0008-5472.CAN-12-3544. Epub 2012 Dec 7.
The Th2 cytokines interleukin (IL)-4 and -13 are acknowledged regulators of lymphocyte proliferation and activation. They have also been well studied in the regulation of various myeloid-derived populations in tumor biology. It has become clear, however, that both cytokines can have direct effects on epithelial tumor cells expressing appropriate receptors. Changes in tumor proliferation, survival, and metastatic capability have all been ascribed to IL-4 and/or IL-13 action. Here, we evaluate the evidence to support direct tumor-promoting roles of these cytokines. We also identify the questions that should be addressed before proceeding with therapeutic approaches based on neutralization of IL-4 or IL-13 pathways.
Th2 细胞因子白细胞介素 (IL)-4 和 -13 是公认的淋巴细胞增殖和激活调节剂。它们在肿瘤生物学中各种髓系来源的群体调节方面也得到了很好的研究。然而,人们已经清楚地认识到,这两种细胞因子都可以对表达适当受体的上皮肿瘤细胞产生直接影响。肿瘤增殖、存活和转移能力的变化都归因于 IL-4 和/或 IL-13 的作用。在这里,我们评估了支持这些细胞因子直接促进肿瘤作用的证据。我们还确定了在基于中和 IL-4 或 IL-13 途径的治疗方法之前需要解决的问题。